The failure of the Eyenovia CHAPERONE study has seen the company’s stock value drop drastically as it weighs up options and ...

GlobalData forecasts that the prostate cancer market is set to increase by 25% from $475.84 million in 2024 to $596.22 ...

Spirovant has announced the commencement of its Phase I/II study with the first patient receiving a dose of SP-101 to treat ...

Eli Lilly has reported comprehensive outcomes from the SURMOUNT-1 study of tirzepatide for treating pre-diabetic and obese ...

AC Immune’s Phase II trial showed an increase in anti-a-syn antibodies following treatment with the Parkinson’s disease ...

GSK has announced positive headline outcomes from a Phase III trial of Blenrep with bortezomib and dexamethasone for multiple ...

Microbion has reported positive topline results from its Phase II study of pravibismane, a topical treatment for DFI.

Medical advances and better knowledge of health have contributed to increased life expectancy and a growing elderly ...

The two-day Oncology event will see industry experts from across the clinical trial space holding talks on subjects from AI ...

Lyophilization plays a crucial role in successful biologic molecule development, but what is lyophilization – and how can it ...

Despite this success, investors were unimpressed with the topline data, with Syndax’s stock dropping by 25.6%, from $21.78 ...

Longboard has commenced the Phase III DEEp OCEAN Study of bexicaserin for treating seizures linked to DEEs in two years and ...